findmyKOL
Clinical trialNCT01339039TerminatedPhase 1Interventional

Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

SponsorPatrick Y. Wen, MDEnrollment26Anaplastic Astrocytoma (AA)Anaplastic Oligodendroglioma (AO)High Grade Glioma: Glioblastoma (GBM)High Grade Glioma: GliosarcomaMixed Anaplastic Oligoastrocytoma (AOA)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →Plerixafor →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2011
Primary completion
30 Apr 2014
Completion
8 Apr 2017
Last update posted
17 Nov 2017
Registered enrollment
26
Registry id
NCT01339039
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.